Developer docs
API playgroundTry for free, no card

Search company profiles

Avalon Ventures

Full company profile

uuid0000jmg

Namestring
Avalon Ventures
Legal namestring
Avalon Ventures, LLC
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Avalon Ventures, LLC is a private, early-stage venture capital firm founded by Kevin Kinsella, operating from offices in La Jolla, California and Cambridge, Massachusetts. The firm focuses on seed and early-stage company formation and financing across two sectors: life sciences (biotechnology and pharmaceuticals) and information technology (wireless, software, media technology, and internet infrastructure). Avalon's investment vehicle is a series of at least eight fund vintages (Avalon V through Avalon VIII), and the firm additionally runs an Accelerator program that embeds CFO and operational services into portfolio companies rather than providing capital alone.

Avalon does not develop proprietary technology products; its offering to entrepreneurs consists of equity capital, company formation expertise, board-level governance, and operational support. The firm differentiates itself through a team of former entrepreneurs and operating executives — including founder Kevin Kinsella (125+ companies formed), Managing Director Jay Lichter Ph.D. (25 investments, $6B+ in biotech transactions, 250+ patents), Director Brady Bohrmann (75+ companies across IT and biotech), Director Steve Tomlin (wireless/IT/media), and Partner Rich Levandov (former Phoenix Technologies co-founder and AOL VP) — alongside CFO Tighe Reardon, who serves as CFO of the Accelerator and its portfolio companies.

Avalon earns revenue through traditional venture capital economics: management fees charged on assets under management across its fund vintages and carried interest realized from successful portfolio company exits. Documented exits include Vertex Pharmaceuticals, Onyx Pharmaceuticals, Synaptics, Vocera Communications, Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Synthorx (acquired by Sanofi), PersonaLogic (acquired by AOL), XenoPharm (acquired by Deltagen), and Sytera (acquired by Sirion Therapeutics). Marketing and deal sourcing rely on founder/entrepreneur networks and industry event participation rather than outbound sales channels, consistent with a sales-led relationship-driven GTM motion targeting passionate entrepreneurs pursuing disruptive ideas in changing market environments.

Short descriptiontext

Avalon Ventures is a private, early-stage venture capital firm founded in 1980 that forms and finances seed-stage companies in life sciences and information technology through multiple fund vintages and an embedded Accelerator program, serving passionate entrepreneurs pursuing disruptive ideas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
seed venture capital, early-stage investing, life sciences investment, information technology investing, startup company formation
Industry2 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Management fees and carried interest
TypeLicensing Royalties
Description

Venture capital revenue is generated through management fees charged on assets under management and carried interest (performance fees) from successful portfolio company exits, including IPOs and acquisitions.

avalon-ventures.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Avalon Ventures is an early-stage venture capital firm that forms and finances seed and early-stage companies in the life sciences and information technology sectors. It deploys capital through successive investment funds (Avalon V through Avalon VIII) and supplements investments with an Accelerator program providing CFO services and operational support to portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 125+ early-stage companies formed and financed over 30+ years
+2 more records
Product overview1 text field

Avalon Ventures is a venture capital firm specializing in seed and early-stage company investments across life sciences and information technology sectors. The firm operates through investment funds (Avalon V through Avalon VIII) and an Accelerator program. The investment strategy focuses on disruptive ideas in changing market environments, with team members specializing in different sectors including biotechnology, pharmaceuticals, wireless technology, IT, and media technology. The Accelerator program provides CFO services and operational support to portfolio companies. As a VC firm, Avalon Ventures does not offer a traditional product; its offering consists of capital investment, mentorship, and operational support to early-stage companies rather than a commercial product or service.

Product and service2 records
1Avalon Ventures Investment Funds (Avalon V through Avalon VIII)
CategoryVenture Capital Funds
Description

Seed and early-stage equity investment funds for entrepreneurs and startups in life sciences and information technology sectors. Each fund is structured as a venture capital vehicle investing in exchange for equity ownership in portfolio companies.

2Avalon Accelerator Program
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage venture capital firm focused exclusively on life sciences, operating an incubator-style model that forms and finances biotech startups. Direct peer to Avalon in life-sciences company formation, sector focus, and seed/Series A stage.

TypeDirect peer
Description

Early-stage life sciences venture capital firm focused on formation and Series A investing in biotech and platform companies. Comparable to Avalon in its emphasis on company creation, sector specialization, and seed-stage focus in therapeutics.

TypeDirect peer
Description

Healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services with significant company-formation activity. Overlaps with Avalon's life-sciences company-creation model and biotech investment stage.

TypeDirect peer
Description

Early-stage venture firm that co-founds and builds technology and life-sciences companies from inception. Strong overlap with Avalon in deep-tech and biotech formation, and in providing early operational and capital support.

TypeDirect peer
Description

Healthcare-dedicated venture capital firm investing across life sciences and healthcare services from seed to growth. Comparable to Avalon in life-sciences focus, though typically with larger fund sizes and broader stage range.

TypeDirect peer
Description

Healthcare-focused venture capital firm with deep biotech company-creation capabilities through its incubator model. Directly comparable to Avalon's life-sciences company-formation and early-stage investing model.

TypeBroad incumbent
Description

Large multi-stage venture firm with significant life-sciences and technology practices. Represents the broader-incumbent category: Avalon competes for the same biotech and IT deals but NEA operates at meaningfully larger fund sizes and broader stages.

TypeEmerging player
Description

Early-stage venture firm investing in science and technology-driven companies, including biotech and deep tech. Comparable to Avalon's IT and life-sciences seed focus, though typically invests at slightly later stages and with larger initial checks.

TypeBroad incumbent
Description

Mega-fund venture firm with dedicated bio/health and IT funds competing for the same founder relationships. Avalon is a smaller, more specialist alternative to a16z's broader bio+tech offering.

TypeDirect peer
Description

Early-stage venture capital firm co-founded by Brady Bohrmann (now at Avalon) in 1997, focused on IT and biotech. Direct peer in early-stage sector focus and stage, and shares team lineage with Avalon.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment191 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avalon Ventures

Venture Capitalavalon-ventures.com

Avalon Ventures is a private, early-stage venture capital firm founded in 1980 that forms and finances seed-stage companies in life sciences and information technology through multiple fund vintages and an embedded Accelerator program, serving passionate entrepreneurs pursuing disruptive ideas.

What Avalon Ventures does

Avalon Ventures, LLC is a private, early-stage venture capital firm founded by Kevin Kinsella, operating from offices in La Jolla, California and Cambridge, Massachusetts. The firm focuses on seed and early-stage company formation and financing across two sectors: life sciences (biotechnology and pharmaceuticals) and information technology (wireless, software, media technology, and internet infrastructure). Avalon's investment vehicle is a series of at least eight fund vintages (Avalon V through Avalon VIII), and the firm additionally runs an Accelerator program that embeds CFO and operational services into portfolio companies rather than providing capital alone.

Avalon does not develop proprietary technology products; its offering to entrepreneurs consists of equity capital, company formation expertise, board-level governance, and operational support. The firm differentiates itself through a team of former entrepreneurs and operating executives — including founder Kevin Kinsella (125+ companies formed), Managing Director Jay Lichter Ph.D. (25 investments, $6B+ in biotech transactions, 250+ patents), Director Brady Bohrmann (75+ companies across IT and biotech), Director Steve Tomlin (wireless/IT/media), and Partner Rich Levandov (former Phoenix Technologies co-founder and AOL VP) — alongside CFO Tighe Reardon, who serves as CFO of the Accelerator and its portfolio companies.

Avalon earns revenue through traditional venture capital economics: management fees charged on assets under management across its fund vintages and carried interest realized from successful portfolio company exits. Documented exits include Vertex Pharmaceuticals, Onyx Pharmaceuticals, Synaptics, Vocera Communications, Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Synthorx (acquired by Sanofi), PersonaLogic (acquired by AOL), XenoPharm (acquired by Deltagen), and Sytera (acquired by Sirion Therapeutics). Marketing and deal sourcing rely on founder/entrepreneur networks and industry event participation rather than outbound sales channels, consistent with a sales-led relationship-driven GTM motion targeting passionate entrepreneurs pursuing disruptive ideas in changing market environments.

Avalon Ventures firmographics

Firmographics
Name
Avalon Ventures
Legal name
Avalon Ventures, LLC
Website
https://avalon-ventures.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
11–50 employees
Short description
Avalon Ventures is a private, early-stage venture capital firm founded in 1980 that forms and finances seed-stage companies in life sciences and information technology through multiple fund vintages and an embedded Accelerator program, serving passionate entrepreneurs pursuing disruptive ideas.
Ownership category
akta.pro rank

Avalon Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)

Keywords

  • Seed venture capital
  • Early-stage investing
  • Life sciences investment
  • Information technology investing
  • Startup company formation

Where Avalon Ventures is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Avalon Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management fees and carried interest: Venture capital revenue is generated through management fees charged on assets under management and carried interest (performance fees) from successful portfolio company exits, including IPOs and acquisitions.

Go-to-market motion1 record

Marketing channels2 records

Avalon Ventures product offering

Product offering

Core offering

Avalon Ventures is an early-stage venture capital firm that forms and finances seed and early-stage companies in the life sciences and information technology sectors. It deploys capital through successive investment funds (Avalon V through Avalon VIII) and supplements investments with an Accelerator program providing CFO services and operational support to portfolio companies.

Product overview

Avalon Ventures is a venture capital firm specializing in seed and early-stage company investments across life sciences and information technology sectors. The firm operates through investment funds (Avalon V through Avalon VIII) and an Accelerator program. The investment strategy focuses on disruptive ideas in changing market environments, with team members specializing in different sectors including biotechnology, pharmaceuticals, wireless technology, IT, and media technology. The Accelerator program provides CFO services and operational support to portfolio companies. As a VC firm, Avalon Ventures does not offer a traditional product; its offering consists of capital investment, mentorship, and operational support to early-stage companies rather than a commercial product or service.

Differentiator

Problem solved

Functional benefit

Products and services

  • Avalon Ventures Investment Funds (Avalon V through Avalon VIII) Seed and early-stage equity investment funds for entrepreneurs and startups in life sciences and information technology sectors. Each fund is structured as a venture capital vehicle investing in exchange for equity ownership in portfolio companies.
  • Avalon Accelerator Program

Quantifiable outcome

  • 125+ early-stage companies formed and financed over 30+ years
  • +2 more outcomes

Companies that use Avalon Ventures

Customer profile

Segments1 record

Ideal customer profiles2 records

Avalon Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Avalon Ventures partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Avalon Ventures competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Early-stage venture capital firm focused exclusively on life sciences, operating an incubator-style model that forms and finances biotech startups. Direct peer to Avalon in life-sciences company formation, sector focus, and seed/Series A stage.
  • 5AM Ventures: Early-stage life sciences venture capital firm focused on formation and Series A investing in biotech and platform companies. Comparable to Avalon in its emphasis on company creation, sector specialization, and seed-stage focus in therapeutics.
  • Versant Ventures: Healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services with significant company-formation activity. Overlaps with Avalon's life-sciences company-creation model and biotech investment stage.
  • ARCH Venture Partners: Early-stage venture firm that co-founds and builds technology and life-sciences companies from inception. Strong overlap with Avalon in deep-tech and biotech formation, and in providing early operational and capital support.
  • Frazier Healthcare Partners: Healthcare-dedicated venture capital firm investing across life sciences and healthcare services from seed to growth. Comparable to Avalon in life-sciences focus, though typically with larger fund sizes and broader stage range.
  • SV Health Investors: Healthcare-focused venture capital firm with deep biotech company-creation capabilities through its incubator model. Directly comparable to Avalon's life-sciences company-formation and early-stage investing model.
  • Masthead Venture Partners: Early-stage venture capital firm co-founded by Brady Bohrmann (now at Avalon) in 1997, focused on IT and biotech. Direct peer in early-stage sector focus and stage, and shares team lineage with Avalon.

Broad incumbents

  • New Enterprise Associates (NEA): Large multi-stage venture firm with significant life-sciences and technology practices. Represents the broader-incumbent category: Avalon competes for the same biotech and IT deals but NEA operates at meaningfully larger fund sizes and broader stages.
  • Andreessen Horowitz (a16z): Mega-fund venture firm with dedicated bio/health and IT funds competing for the same founder relationships. Avalon is a smaller, more specialist alternative to a16z's broader bio+tech offering.

Emerging players

  • Lux Capital: Early-stage venture firm investing in science and technology-driven companies, including biotech and deep tech. Comparable to Avalon's IT and life-sciences seed focus, though typically invests at slightly later stages and with larger initial checks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Avalon Ventures social profiles

Digital presence

Avalon Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avalon Ventures leadership team

Management profile

Number of profiles

Profiles6 records

Avalon Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avalon Ventures M&A and investment

M&A and investment

M&A

Investments191 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avalon Ventures

What does Avalon Ventures do?

Avalon Ventures is an early-stage venture capital firm that forms and finances seed and early-stage companies in the life sciences and information technology sectors. It deploys capital through successive investment funds (Avalon V through Avalon VIII) and supplements investments with an Accelerator program providing CFO services and operational support to portfolio companies.

Is Avalon Ventures a public or private company?

Avalon Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Avalon Ventures founded?

Avalon Ventures was founded in 1980. It employs 11 to 50 people.

Where is Avalon Ventures based?

Avalon Ventures is headquartered in La Jolla, United States, in the North America region.

How does Avalon Ventures make money?

One revenue line is on record: management fees and carried interest.

Who are Avalon Ventures's main competitors?

Direct peers on record are Atlas Venture, 5AM Ventures, Versant Ventures, ARCH Venture Partners, Frazier Healthcare Partners, SV Health Investors and Masthead Venture Partners. Broad incumbents are New Enterprise Associates (NEA) and Andreessen Horowitz (a16z). Lux Capital is listed as an emerging player.

Does Avalon Ventures have an API?

No public API is recorded for Avalon Ventures.

What industry is Avalon Ventures in?

Avalon Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAM, Accelerators & Incubators (Investor-Operated). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SeafoodSourceInvestor panel offers blue biotech startups top tips on getting capital investmentsAt the inaugural North Atlantic Blue BioTech Summit, a panel of investors advised blue biotech startups on securing capital, emphasizing that capital availability is not the issue but rather connecting entrepreneurs with the right sources. The investors, including representatives from Avalon Ventures and RA Capital Management, shared practical tips such as having a refined pitch, treating all firm contacts with respect, and understanding screening criteria. The panelists noted that blue biotech faces unique challenges because the industry is so new that companies must first explain their products before convincing investors of their worth.GlobeNewswireCullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619Cullinan Oncology increased its ownership in MICA subsidiary from 54% to 92% by purchasing equity from Avalon Ventures and Bregua Corporation for $30.7 million. MICA holds worldwide rights to CLN-619, a monoclonal antibody targeting the MICA/MICB pathway, with an ongoing Phase I trial. Initial clinical data is expected in mid-2023.FinSMEsFortis Therapeutics Raises $40M in Series A FundingFortis Therapeutics closed a $40M Series A financing led by Avalon Ventures, Bregua Corporation, and others. The funds will advance FOR46 in clinical trials for relapsed/refractory multiple myeloma and metastatic castration-resistant prostate cancer, with expansion cohorts now enrolling.socaltech.comNerio Therapeutics Finds $3.0MNerio Therapeutics, a La Jolla-based life sciences company, raised $3.0M in funding disclosed in a regulatory filing. The funding is part of an ongoing $5.7M raising effort, and the company appears to be emerging from COI Pharmaceuticals, an incubator created by Avalon Ventures.FinSMEsSeva Raises $2.4M in Seed FundingSeva, a NYC-based knowledge management platform, raised $2.4M in seed funding led by Avalon Ventures. The company will use the funds to grow its engineering capabilities. It is accepting companies into its Beta and plans new integrations with Office 365 and Salesforce.PR NewswireSynthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ CytokinesSynthorx Inc. completed a $63 million Series C financing round led by OrbiMed, with participation from new investors Medicxi and Osage University Partners, as well as existing investors Avalon Ventures, RA Capital Management, and Correlation Ventures. The proceeds will advance the company's pipeline of Synthorin cytokines, including an IL-2 molecule engineered using the company's expanded genetic alphabet technology for enhanced immuno-oncology applications. Peter Thompson of OrbiMed and independent advisor Vickie Capps will join Synthorx's board of directors.FinSMEsAveron Closes $13.3M Funding RoundAveron closed a $5M Series A1 round led by Avalon Ventures and Salesforce founder Marc Benioff, bringing total Series A funding to $13.3M. The funds will accelerate its mobile identity verification expansion and team growth. The company's Wi-Fi/LTE authentication standard is used by ridesharing, crypto, and telecom firms.socaltech.comAvalon Ventures Backs Averon For Mobile Identity VerificationAveron, a mobile identity verification software developer, raised $5M in a Series A1 round led by Avalon Ventures, with Marc Benioff participating. The company has now raised $13.3M in total funding. The investment was managed by Brady Bohrmann.TechCrunchAveron closes $8.3M funding to make your smartphone the key to ID onlineAveron, a San Francisco startup, closed an $8.3 million Series A round led by Avalon Ventures. The company's Direct Autonomous Authentication (DAA) uses mobile network signals and SIM/eSIM chips to create frictionless, secure identity verification. The technology aims to reduce exposure to cybercriminals.FinSMEsAveron Closes $8.3M Series A FundingAveron, a San Francisco-based developer of Direct Autonomous Authentication (DAA) solutions, closed an $8.3 million Series A financing led by Avalon Ventures. The company will use the funds to accelerate its rollout strategy, and Avalon Ventures partners Rich Levandov and Brady Borhmann will join its board.